AR070844A1 - Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 - Google Patents
Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2Info
- Publication number
- AR070844A1 AR070844A1 ARP090100889A ARP090100889A AR070844A1 AR 070844 A1 AR070844 A1 AR 070844A1 AR P090100889 A ARP090100889 A AR P090100889A AR P090100889 A ARP090100889 A AR P090100889A AR 070844 A1 AR070844 A1 AR 070844A1
- Authority
- AR
- Argentina
- Prior art keywords
- fab fragment
- humanized monoclonal
- fab
- type
- diabetes
- Prior art date
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title abstract 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title abstract 6
- 108010063919 Glucagon Receptors Proteins 0.000 title abstract 3
- 102100040890 Glucagon receptor Human genes 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 241001529936 Murinae Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Fragmento Fab o anticuerpo monoclonal humanizado que comprende el fragmento Fab, donde dicho fragmento Fab es capaz de enlazar a los receptores de glucagon de humano, rata y murino e inhiben el enlace de glucagon para cada receptor con un Ki de menos de 50nM, antagonistas del polipéptido del receptor de glucagon los cuales inhiben el enlace de la hormona de glucagon a su receptor. Vector que comprende una secuencia de ácido nucleico que codifica dicho fragmento Fab o anticuerpo monoclonal humanizado y célula huésped que comprende una secuencia del polinucleotido heterologo que codifica dicho fragmento Fab o anticuerpo monoclonal humanizado. Composicion farmacéutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento o prevencion de diabetes de tipo 1 o tipo 2 o para lograr la pérdida de peso en un humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3990708P | 2008-03-27 | 2008-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070844A1 true AR070844A1 (es) | 2010-05-05 |
Family
ID=40794248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100889A AR070844A1 (es) | 2008-03-27 | 2009-03-12 | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7968686B2 (es) |
| EP (1) | EP2268670A1 (es) |
| JP (1) | JP5438095B2 (es) |
| KR (1) | KR101235934B1 (es) |
| CN (1) | CN101983208A (es) |
| AR (1) | AR070844A1 (es) |
| AU (1) | AU2009228866A1 (es) |
| BR (1) | BRPI0910118A2 (es) |
| CA (1) | CA2719761A1 (es) |
| CL (1) | CL2009000586A1 (es) |
| EA (1) | EA201071126A1 (es) |
| MX (1) | MX2010010517A (es) |
| PE (1) | PE20091674A1 (es) |
| TW (1) | TW201000126A (es) |
| WO (1) | WO2009120530A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482350B (zh) * | 2009-09-08 | 2015-08-05 | 株式会社新药 | 作用于胰高血糖素受体的抗体及其应用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013059531A1 (en) * | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
| EP2785740A1 (en) | 2011-12-02 | 2014-10-08 | Eli Lilly and Company | Anti-glucagon antibodies and uses thereof |
| SG11201508264UA (en) * | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
| CA2950695C (en) * | 2014-06-08 | 2022-12-06 | REMD Biotherapeutics, Inc | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| WO2018044903A1 (en) | 2016-08-30 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| MX2019008722A (es) | 2017-01-27 | 2019-10-02 | Ngm Biopharmaceuticals Inc | Proteínas de unión al receptor de glucagón y métodos para usarlas. |
| US20210130480A1 (en) | 2017-08-22 | 2021-05-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| US10961315B2 (en) | 2018-07-27 | 2021-03-30 | Ngm Biopharmaceuticals, Inc. | Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody |
| CN112996811B (zh) | 2018-12-21 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| CA2142819C (en) | 1992-08-28 | 2003-08-19 | Wayne R. Kindsvogel | Glucagon receptors |
| AU2002239538A1 (en) | 2000-12-06 | 2002-06-18 | Deltagen, Inc. | Transgenic mice containing glucagon receptor gene disruptions |
| AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CN101484081A (zh) | 2006-07-04 | 2009-07-15 | 布拉科成像S.P.A.公司 | 生物组织尤其是肿瘤组织等的局部热切除装置 |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
-
2009
- 2009-03-12 CL CL2009000586A patent/CL2009000586A1/es unknown
- 2009-03-12 AR ARP090100889A patent/AR070844A1/es unknown
- 2009-03-12 PE PE2009000369A patent/PE20091674A1/es not_active Application Discontinuation
- 2009-03-13 TW TW098108296A patent/TW201000126A/zh unknown
- 2009-03-17 JP JP2011501904A patent/JP5438095B2/ja not_active Expired - Fee Related
- 2009-03-17 CA CA2719761A patent/CA2719761A1/en not_active Abandoned
- 2009-03-17 US US12/405,458 patent/US7968686B2/en not_active Expired - Fee Related
- 2009-03-17 MX MX2010010517A patent/MX2010010517A/es not_active Application Discontinuation
- 2009-03-17 WO PCT/US2009/037349 patent/WO2009120530A1/en active Application Filing
- 2009-03-17 EP EP09726006A patent/EP2268670A1/en not_active Withdrawn
- 2009-03-17 KR KR1020107021297A patent/KR101235934B1/ko not_active IP Right Cessation
- 2009-03-17 EA EA201071126A patent/EA201071126A1/ru unknown
- 2009-03-17 AU AU2009228866A patent/AU2009228866A1/en not_active Abandoned
- 2009-03-17 BR BRPI0910118A patent/BRPI0910118A2/pt not_active IP Right Cessation
- 2009-03-17 CN CN2009801107130A patent/CN101983208A/zh active Pending
-
2011
- 2011-05-16 US US13/108,073 patent/US20110212092A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101235934B1 (ko) | 2013-02-21 |
| CA2719761A1 (en) | 2009-10-01 |
| US20110212092A1 (en) | 2011-09-01 |
| AU2009228866A1 (en) | 2009-10-01 |
| MX2010010517A (es) | 2010-12-20 |
| TW201000126A (en) | 2010-01-01 |
| US7968686B2 (en) | 2011-06-28 |
| US20090252727A1 (en) | 2009-10-08 |
| EP2268670A1 (en) | 2011-01-05 |
| JP2011518125A (ja) | 2011-06-23 |
| WO2009120530A1 (en) | 2009-10-01 |
| JP5438095B2 (ja) | 2014-03-12 |
| PE20091674A1 (es) | 2009-11-04 |
| KR20100117130A (ko) | 2010-11-02 |
| BRPI0910118A2 (pt) | 2015-12-29 |
| CL2009000586A1 (es) | 2010-06-04 |
| EA201071126A1 (ru) | 2011-04-29 |
| CN101983208A (zh) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070844A1 (es) | Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2 | |
| CL2017003351A1 (es) | Anticuerpo anti receptor de transferrina humana que pasan a través de la barrera hematoencefálica. | |
| CY1122539T1 (el) | Αναλογα γλυκαγονης | |
| ECSP12012351A (es) | Análogos de glucagón | |
| CR10736A (es) | Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon | |
| CR20230302A (es) | MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380) | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| EA201590294A1 (ru) | Аналоги глюкагона | |
| MX2020012240A (es) | Agentes de ligacion agonistas del receptor tnf. | |
| CL2014002791A1 (es) | Polipéptido que comprende un agonista del receptor de glp-1/glucagón, particularmente oxintomodulina (oxm), unido a al menos un péptido c-terminal de gonadotrofina corionica; método de producción; y uso para prevenir aumento de peso. | |
| CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| EA201791057A1 (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf | |
| PE20150648A1 (es) | Proteinas de fusion para el tratamiento de un sindrome metabolico | |
| CL2013003688A1 (es) | Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa. | |
| CL2013001468A1 (es) | Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre. | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| BR112012028707A2 (pt) | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. | |
| AR093788A1 (es) | Inmunoterapia con agentes de enlace | |
| CL2007002085A1 (es) | Anticuerpo o fragmento del mismo especifico para el receptor epha2; polinucleotido que lo codifica; vector y celula huesped que lo comprenden; hibridoma; conjugados del mismo con agentes citotoxicos; composicion farmaceutica que los comprende;su uso | |
| CR20130126A (es) | Anticuerpos anti-ox40 y métodos de uso de los mismos | |
| CL2012002635A1 (es) | Péptido que presenta actividad para el receptor del péptido insulinotrópico dependiente de glucosa (gip-r) y para el receptor del péptido-1 similar al glucagón (glp-1-r) y son selectivos sobre el receptor del glucagón (gluc-r); formulación farmacéutica que lo comprende; y su uso para el tratamiento de diabetes mellitus y para la pérdida de peso. | |
| PE20190917A1 (es) | Compuestos del peptido tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido | |
| BR112017022009A2 (pt) | ?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico? | |
| AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |